Found: 5
Select item for more details and to access through your institution.
236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-236-OR
- By:
- Publication type:
- Article
149-OR: Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-149-OR
- By:
- Publication type:
- Article
750-P: Afinion HbA1c Dx Point-of-Care Test Is Accurate to Diagnose Diabetes in CLIA-Waived Settings.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-750-P
- By:
- Publication type:
- Article
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 6, p. 517, doi. 10.1002/cpdd.261
- By:
- Publication type:
- Article
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article